Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials — Whole blood cytokine release assays are poorly predictive for TGN1412 cytokine storm-Reference-Cited by-同舟云学术

Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials — Whole blood cytokine release assays are poorly predictive for TGN1412 cytokine storm

Published:2015-09 Issue: Volume:424 Page:43-52
ISSN:0022-1759
Container-title:Journal of Immunological Methods
language:en
Short-container-title:Journal of Immunological Methods

Author:

Vessillier S.^ORCID,Eastwood D.,Fox B.,Sathish J.,Sethu S.,Dougall T.^ORCID,Thorpe S.J.,Thorpe R.,Stebbings R.^ORCID

Funder

UK Department of Health

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference49 articles.

1. CD28-mediated co-stimulation: a quantitative support for TCR signalling;Acuto;Nat. Rev. Immunol.,2003

2. Effect of a single amino acid mutation on the activating and immunosuppressive properties of a “humanized” OKT3 monoclonal antibody;Alegre;J. Immunol.,1992

3. Critical parameters in blood processing for T-cell assays: validation on ELISpot and tetramer platforms;Afonso;J. Immunol. Methods,2010

4. Rituximab, anti-CD20, induces in vivo cytokine release but does not impair ex vivo T-cell responses;Agarwal;Am. J. Transplant.,2004

5. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies;Ascierto;Semin. Oncol.,2010

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune‐related adverse events of antibody‐based biological medicines in cancer therapy;Journal of Cellular and Molecular Medicine;2024-07

2. Beyond MABEL: An Integrative Approach to First in Human Dose Selection of Immunomodulators by the Health and Environmental Sciences Institute (HESI) Immuno‐Safety Technical Committee (ITC);Clinical Pharmacology & Therapeutics;2024-06-07

3. Severe cytokine release syndrome induced by immune checkpoint inhibitors in cancer patients – A case report and review of the literature;Heliyon;2024-01

4. Biomarkers in Nonclinical Drug Development;A Comprehensive Guide to Toxicology in Nonclinical Drug Development;2024

5. Ex vivo comparative immunogenicity assessment (EVCIA) to determine relative immunogenicity in chronic plaque psoriasis in participants receiving Humira® or undergoing repeated switches between Humira® and AVT02;Immunotherapy Advances;2023-12-21